New mRNA HIV vaccines enter early human testing
NCT ID NCT07569029
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-stage trial will test two experimental mRNA vaccines designed to teach the immune system to make antibodies that target HIV. About 42 adults with well-controlled HIV will receive the vaccines and then temporarily pause their regular HIV medication under close monitoring. The main goals are to check safety and see if the vaccines can trigger or boost specific immune responses against the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
two experimental mRNA HIV vaccines (DV700P-RNA and DV701B1.1-RNA)
What this could lead to
If successful, this could point toward a vaccine that helps the immune system better control HIV, potentially reducing the need for daily antiretroviral therapy.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The vaccines may not produce strong or lasting immune responses, and the planned pause in HIV medication carries risks of viral rebound.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS (Site ID: 31788)
Birmingham, Alabama, 35222, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Barranco CRS (Site ID: 11301)
Lima, 15063, Peru
Contact Phone: •••-•••-••••
-
Beth Israel Deaconess Medical Center / BIDMC VCRS (Site ID: 32077)
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)
Bellavista, Provincia Constitucional del Callao, 07006, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundacion Huesped CRS (Site ID: 31957)
Buenos Aires, C1427CEA, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
San Miguel CRS (Site ID: 11302)
Lima, 15088, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seattle Vaccine and Prevention CRS (Site ID: 30331)
Seattle, Washington, 98109, United States
Contact Email: •••••@•••••
-
Seke South CRS/30294 University of Zimbabwe -Clinical Trials Research Centre (UZ-CTRC)
Harare, Zimbabwe
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Spilhaus CRS/30314 University of Zimbabwe -Clinical Trials Research Centre (UZ-CTRC)
Harare, Zimbabwe
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ponce de Leon Center CRS (Site ID: 5802)
Atlanta, Georgia, 30308, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Via Libre CRS (Site ID: 31909)
Lima, 15001, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••